Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors

Author: ScaleReady

Standardization, Simplification, and Cost Reduction for Lifesaving Therapies

We’re excited to announce a collaborative effort between Multiply Labs, a leader in automated manufacturing systems for personalized medicine, and Wilson Wolf Corporation, a pioneer in cell and gene-modified therapy (CGT) technology. This partnership focuses on automating Wilson Wolf’s innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.

Shared Vision for Accessible Therapies

Both Multiply Labs and Wilson Wolf share a commitment to making potentially lifesaving cell and gene therapies more accessible. This collaboration will achieve this goal by:

Standardization: Simplifying the CGT manufacturing process through automation, reducing reliance on highly skilled labor.
Cost Reduction: Lowering manufacturing costs, making these therapies more affordable for patients.
High-Throughput Manufacturing: Enabling large-scale production using a “ballroom” setting with automated G-Rex® bioreactors.

G-Rex®: An ideal Platform for Automation

Wilson Wolf’s G-Rex® bioreactors are uniquely suited for automation due to their:

Closed System Design: Provides cells with continuous oxygen and nutrients, eliminating the need for manual intervention.
All-in-One Functionality: Acts as a single unit for activation, transduction, expansion, and concentration, simplifying the manufacturing process.
High Throughput Potential: Enables seamless integration with automated systems for large-scale production.

Scientific Validation and Industry Recognition

Multiply Labs’ robotic system, designed for T cell therapy expansion with G-Rex® bioreactors, has received validation through a peer-reviewed publication in Cytotherapy, a leading journal in the field. Industry estimates suggest this technology has the potential to reduce cell therapy manufacturing costs by a staggering 70%.

The Future of Cell Therapy Manufacturing

This collaboration between Multiply Labs and Wilson Wolf Corporation represents a significant leap forward in cell therapy manufacturing. By automating G-Rex® bioreactors, we pave the way for increased accessibility of these life-saving treatments to a broader patient population.

Stay tuned for further updates on this exciting partnership and its impact on the future of cell and gene therapy!

Watch the video

Related Blog

Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy

Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.

Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success

Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.

Advancing Immune Cell Therapies Through Efficient Cell Culture Techniques

In an expert roundtable discussion by Cell and Gene Therapy Insights, the potential of cell culture in immune cell therapies takes center stage, offering promising possibilities for the future of regenerative medicine.

Josh Ludwig Discusses Innovative Approaches to Cell & Gene Therapy Manufacturing in Medical Alley Podcast

In an enlightening episode of the Medical Alley Podcast, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, shares invaluable insights into the world of cell and gene therapy manufacturing.

Josh Ludwig Shares Vision for Streamlined Cell and Gene Therapy with Medical Alley

In an interview published by Medical Alley, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, discussed ScaleReady's innovative approach to revolutionizing the cell and gene therapy industry.

Josh Ludwig Shares Insights on Achieving Scalable and Cost-Effective Cell and Gene Therapy Manufacturing

This interview provides valuable insights into Ludwig's vision for the future of CGT manufacturing, focusing on creating a robust and accessible platform that empowers the industry to deliver life-changing therapies to patients worldwide.

Early Adoption and Partnerships — The Secret to Commercialization Success in Regenerative Medicine

The power of collaborative partnerships is highlighted as a game-changer in driving commercialization efforts. By leveraging the expertise of multiple stakeholders, including researchers, clinicians and industry players, cell and gene therapy manufacturers can navigate complex challenges and accelerate the delivery of groundbreaking therapies to patients.

Simplifying Processes and Prioritizing Standardization: A Better Approach to Scaling Cell and Gene Therapies

The road to scaling cell and gene therapies successfully lies in prioritizing simplicity and standardization. By addressing complexity first and then implementing automation strategically, the industry can bring life-changing treatments to more patients worldwide.

Are you ready to scale

Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.

Meet the Author

ScaleReady